Literature DB >> 27766185

Validation of true low-dose 18F-FDG PET of the brain.

David Fällmar1, Johan Lilja2, Lena Kilander3, Torsten Danfors4, Mark Lubberink4, Elna-Marie Larsson1, Jens Sörensen4.   

Abstract

The dosage of 18F-FDG must be sufficient to ensure adequate PET image quality. For younger patients and research controls, the lowest possible radiation dose should be used. The purpose of this study was to find a protocol for FDG-PET of the brain with reduced radiation dose and preserved quantitative characteristics. Eight patients with neurodegenerative disorders and nine controls (n=17) underwent FDG-PET/CT twice on separate occasions, first with normal-dose (3 MBq/kg), and second with low-dose (0.75 MBq/kg, 25% of the original). Five additional controls (total n=22) underwent FDG-PET twice, using normal-dose and ultra-low-dose (0.3 MBq/kg, 10% of original). All subjects underwent MRI. Ten-minute summation images were spatially normalized and intensity normalized. Regional standard uptake value ratios (SUV-r) were calculated using an automated atlas. SUV-r values from the normal- and low-dose images were compared pairwise. No clinically significant bias was found in any of the three groups. The mean absolute difference in regional SUV-r values was 0.015 (1.32%) in controls and 0.019 (1.67%) in patients. The ultra-low-dose protocol produced a slightly higher mean difference of 0.023 (2.10%). The main conclusion is that 0.75 MBq/kg (56 MBq for a 75-kg subject) is a sufficient FDG dose for evaluating regional SUV-ratios in brain PET scans in adults with or without neurodegenerative disease, resulting in a reduction of total PET/CT effective dose from 4.54 to 1.15 mSv. The ultra-low-dose (0.5 mSv) could be useful in research studies requiring serial PET in healthy controls or children.

Entities:  

Keywords:  FDG; PET; methodology; neurodegeneration; neuroimaging

Year:  2016        PMID: 27766185      PMCID: PMC5069279     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  10 in total

1.  Six-month test-retest reliability of MRI-defined PET measures of regional cerebral glucose metabolic rate in selected subcortical structures.

Authors:  S M Schaefer; H C Abercrombie; K A Lindgren; C L Larson; R T Ward; T R Oakes; J E Holden; S B Perlman; P A Turski; R J Davidson
Journal:  Hum Brain Mapp       Date:  2000-05       Impact factor: 5.038

2.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

3.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

Authors:  Andrea Varrone; Susanne Asenbaum; Thierry Vander Borght; Jan Booij; Flavio Nobili; Kjell Någren; Jacques Darcourt; Ozlem L Kapucu; Klaus Tatsch; Peter Bartenstein; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

Review 4.  The clinical use of structural MRI in Alzheimer disease.

Authors:  Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

5.  Whole-body PET/CT studies with lowered ¹⁸F-FDG doses: the influence of body mass index in dose reduction.

Authors:  Raúl Sánchez-Jurado; Manuel Devis; Rut Sanz; Jose Enrique Aguilar; Maria del Puig Cózar; Jose Ferrer-Rebolleda
Journal:  J Nucl Med Technol       Date:  2014-02-06

6.  Basal ganglia and frontal lobe glucose metabolism. A reproducibility positron emission tomography study.

Authors:  S Goldman; S Dethy; F Lotstra; F Biver; E Stanus; D Wikler; J Hildebrand; J Mendlewicz; A Luxen
Journal:  J Neuroimaging       Date:  1995-10       Impact factor: 2.486

Review 7.  Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging.

Authors:  Valentina Berti; Lisa Mosconi; Alberto Pupi
Journal:  PET Clin       Date:  2014-04

8.  Prediction of standard-dose brain PET image by using MRI and low-dose brain [18F]FDG PET images.

Authors:  Jiayin Kang; Yaozong Gao; Feng Shi; David S Lalush; Weili Lin; Dinggang Shen
Journal:  Med Phys       Date:  2015-09       Impact factor: 4.071

9.  Whole-body PET/CT scanning: estimation of radiation dose and cancer risk.

Authors:  Bingsheng Huang; Martin Wai-Ming Law; Pek-Lan Khong
Journal:  Radiology       Date:  2009-02-27       Impact factor: 11.105

10.  Optimized dose regimen for whole-body FDG-PET imaging.

Authors:  Eleonore H de Groot; Nieky Post; Ronald Boellaard; Nils Rl Wagenaar; Antoon Tm Willemsen; Jorn A van Dalen
Journal:  EJNMMI Res       Date:  2013-08-12       Impact factor: 3.138

  10 in total
  6 in total

1.  Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging.

Authors:  Ying-Hwey Nai; Shoichi Watanuki; Manabu Tashiro; Nobuyuki Okamura; Hiroshi Watabe
Journal:  Radiol Phys Technol       Date:  2018-10-16

2.  Dose Reduction in Brain [18F]FDG PET/MRI: Give It Half a Chance.

Authors:  Marine Soret; Eve Piekarski; Nathanaëlle Yeni; Alain Giron; Jacques-Antoine Maisonobe; Maya Khalifé; Claire Zaslavsky; Marc Bertaux; Marie-Odile Habert; Aurélie Kas
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

3.  Z-score maps from low-dose 18F-FDG PET of the brain in neurodegenerative dementia.

Authors:  David Fällmar; Johan Lilja; Torsten Danfors; Lena Kilander; Victor Iyer; Mark Lubberink; Elna-Marie Larsson; Jens Sörensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

4.  A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination.

Authors:  José V Pardo; Sohail A Sheikh; Graeme Schwindt; Joel T Lee; David E Adson; Barry Rittberg; Faruk S Abuzzahab
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

5.  Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases.

Authors:  Elin Lindström; Jenny Oddstig; Torsten Danfors; Jonas Jögi; Oskar Hansson; Mark Lubberink
Journal:  Neuroimage Clin       Date:  2020-08-19       Impact factor: 4.881

6.  Ultra-low-dose in brain 18F-FDG PET/MRI in clinical settings.

Authors:  Marine Soret; Jacques-Antoine Maisonobe; Serge Desarnaud; Sébastien Bergeret; Valérie Causse-Lemercier; Arnaud Berenbaum; Laura Rozenblum; Marie-Odile Habert; Aurélie Kas
Journal:  Sci Rep       Date:  2022-09-12       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.